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Abstract
C/EBPs are a family of B-Zip transcription factors -TFs- involved in the regulation of differentiation in several tissues. The two
most studied members -C/EBPa and C/EBPb- play important roles in skin homeostasis and their ablation reveals cells with
stem cells signatures. Much less is known about C/EBPd which is highly expressed in the granular layer of interfollicular
epidermis and is a direct target of p63, the master regular of multilayered epithelia. We identified C/EBPd target genes in
human primary keratinocytes by ChIP on chip and profiling of cells functionally inactivated with siRNA. Categorization
suggests a role in differentiation and control of cell-cycle, particularly of G2/M genes. Among positively controlled targets
are numerous genes involved in barrier function. Functional inactivation of C/EBPd as well as overexpressions of two TF
targets -MafB and SOX2- affect expression of markers of keratinocyte differentiation. We performed IHC on skin tumor tissue
arrays: expression of C/EBPd is lost in Basal Cell Carcinomas, but a majority of Squamous Cell Carcinomas showed elevated
levels of the protein. Our data indicate that C/EBPd plays a role in late stages of keratinocyte differentiation.
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Introduction
The skin is a multilayered epithelium that enables organisms to
be protected from the exterior, while keeping homeostasis of fluids.
Skin differentiation is a lifelong process that leads to the expansion
of cells with specific, exquisite features from a relatively few
progenitors that guarantee the maintenance of the stem cells pool.
Renewal of stem cells and ongoing active terminal differentiation
require the progressive fine tuning of transcriptional programs,
which are masterminded by Transcription Factors (TFs). Several
TFs have a role in keratinocytes physiology. Specifically, genetic
experiments established that p63, IRF-6, KLF4, Gata3 and C/
EBPs are important [1].
C/EBPs are a family of six B-Zip TFs that activate and repress
transcription of genes involved in differentiation and growth
control [2]. The two most studied members of the family, C/EBPa
and C/EBPb are required for differentiation of adipocytes and
hematopoietic cells [3–6]. Inactivation of C/EBPe leads to lack of
natural killer cells [7]. C/EBPf -CHOP, DDIT3- is involved in
the response to noxious signals, such as ER-stress and DNA-
damage [8]. C/EBPd KO mice have a mammary phenotype, with
an alteration in the involution of the mammary glands upon
lactation [9,10]. Similarly to C/EBPb adipocyte differentiation is
impaired in cells that lack C/EBPd when cultured in vitro [6].
In the skin, C/EBPa is expressed mostly in the upper layers [10]
and mice with selective ablation of C/EBPa in the skin have no
apparent phenotype in normal conditions, but are subject to
increased RAS-mediated tumorigenesis [11]. C/EBPb is expressed
in the cytoplasm of basal keratinocytes [10] and in the nuclei of the
spinous layer [12]. Mice with selective ablation of C/EBPb in the
skin have epidermal hyperplasia with downplay of Keratin 1 and
10 expression [13]. Contrary to C/EBPa, C/EBPb ablation in the
skin suppresses RAS-mediated tumorigenesis [14–17]. Important-
ly, the combined ablation of C/EBPa and C/EBPb leads to
profound alteration in interfollicular epidermis due to increased
proliferation of basal cells, defective differentiation and insufficient
barrier function [18]. These mice show suprabasal p63 expression.
Vinson’s group reported on a transgenic model expressing a
dominant negative C/EBP –termed A-C/EBP- in basal keratino-
cytes: these mice have hyperplasia of the basal epidermis and
increased apoptosis of the upper layers [19]: p53 and pro-
apoptotic markers are induced and C/EBPb dramatically
reduced. A-C/EBP is not C/EBPb-specific, thus C/EBPd might
contribute to the observed phenotype. Although C/EBPd KO
mice have no apparent skin alterations [20], expression is high in
human interfollicular skin, and negatively regulated by p63 [21].
Importantly, in the multi-layered epithelia of the corneal limbus,
C/EBPd is upstream of p63 and thought to be a marker of
stemness [22].
Recent reports reveal alterations in the structure or expression
levels of C/EBP family members in a variety of human cancers.
For example, down-regulation of C/EBPa is seen in several
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human malignancies, including skin [23], whereas C/EBPb is
overexpressed in carcinogen-induced skin tumors [24] and breast
cancer [25]. Moreover, ‘‘loss of function’’ alterations of CEBPd
and promoter methylation of the C/EBPD locus have been
observed in primary human breast tumors [26,27]. Through ChIP
on chip experiments, C/EBPa and C/EBPb targets were
identified in 3T3-L1 adipocytes [28], and C/EBPd in mammary
cells undergoing growth arrest [29]. To reconstruct the C/EBPd
network in keratinocytes, we identified targets, through the use of
RNAi inactivation coupled to gene expression profiling, and ChIP
on chip technology.
Materials and Methods
Cells and culture conditions
First passage human primary keratinocytes were derived from
breast of healthy individuals undergoing plastic surgery and grown
on a feeder-layer of lethally irradiated 3T3 cells in DMEM F12
added of Insulin (5 mg/ml), EGF-R (10 ng/ml), hydrocortisone
(0.4 mg/ml), T3 (2 nM), Cholera toxin (0.1 nM) and transferrin
(5 mg/ml). The preparation of primary keratinocytes was per-
formed at the‘‘Banca della Cute’’-CTO Hospital in Torino (I), and
the procedure was approved by the Ethics Commettee ‘‘Comitato
Etico Interaziendale S. Giovanni Battista CTO-M.Adelaide’’.
Informed verbal consent from the patients was obtained as stated
in procedure, for which approval was granted by the Ethics
Committee.
RT-PCR and transfections
For RNA profilings, 106 first passage primary keratinocytes
from healthy individuals were transfected with Nucleofector
(Amaxa, D) according to the Manufacturer’ conditions with the
off-target control siRNA oligos (Sigma), or with an oligonucleotide
targeting human C/EBPd GACUCAGCAACGACCCATuu
[21]. The mRNAs were extracted 48 hours after transfections
with the RNA-Easy kit (Qiagen, D). For cDNA synthesis, 2 mg of
RNA were used with M-MLV-RT kit (Invitrogen, USA). Semi-
quantitative PCR analysis o the C/EBPd mRNA were performed
with specific primers (AGTTCTTGGGACATAGGAGCGCA;
GTACCTTAGCTGCATCAACAGGAG). qRT-PCR analysis
was used to validate the profiling arrays, with a Biorad MyIQ
single colour thermal cycler and a SYBR Green PCR Master mix.
Specificity of products was monitored with a heat dissociation
curve, fold enrichment was calculated with the formula 22DCt
where the Ct represented the threshold cycles of the input, the
specific antibody and the negative antibody; a further normaliza-
tion with the enrichment obtained on a negative genomic region
(Centromeric Satellite 11) was applied. A list of the RT-PCR
primers is provided in Table S1. Transfections with 4 mg of Sox2
and MafB expression vectors, or empty pcDNA3 control, were
used; cells were split in two after 24 hours, and one of the culture
was differentiated by addition of 1,4 mM CaCl2.
ChIP on chip
ChIP analysis was carried out with the method described in Ref.
21 with an anti-C/EBPd antibody (Active Motif #39006). The
immunoprecipitated DNA was analyzed with specific primers in
semi-quantitative PCR assays with the primers listed in Table S2.
The generation of amplicons from the individual ChIPs was
performed following the protocol of LM-PCR described in Refs.
30, 31. Briefly, two unidirectional linkers were annealed and
ligated to the chromatin IPs, previously blunted by T4 DNA
polymerase. The first amplicons were generated by PCR (15
cycles). The reaction was purified using the GFX PCR purification
kit (Amersham Biosciences) according to the Manufacturer’s
instructions. A fraction of these initial reactions was used to
generate more amplicons for 30 additional cycles. After purifica-
tion, the DNA was quantified and examined by gene specific PCR
to ensure that the initial enrichment was maintained. 5 mg of
amplicons for Flag and input DNA (subjected to the same number
of PCR manipulations) were labeled using the LabelIT Cy5/Cy3
Nucleic acid labeling kit (Mirus), following the manufacturer’s
instructions, with a reagent to DNA ratio of 2.5 for Cy5 (IPs) and
1.5 for Cy3 (Input). The hybridization and washing conditions for
these slides were described previously [30,31]. The CpG 21K
slides were purchased from University Health Network, Toronto,
Canada. The hybridized microarrays were scanned and analyzed
using a ScanArray 4000 and QuantArray analysis software
(Packard). Features of poor intensity (,500) and those which did
not meet the quality control criteria (visual inspection, spot
circularity, spot uniformity and background uniformity for both
channels) were discarded. After the background subtraction for
each spot, the data were normalized to median, that is, the ratio of
the median value of all spots in the Cy5 channel (IP DNA) and the
ratio of the median value of the control channel (Cy3 Input). The
21K CpG island array was described in Ref. 31. We considered
positive all the clones which satisfied the described criteria: .1.5-
fold enrichment in the C/EBPd samples over the negative
antibody -Flag- samples in each of the performed experiments.
The sequences of the positive CpG islands clones were retrieved
from both the Sanger center (http://www.sanger.ac.uk/HGP/cgi.
shtm) and the UHN Cancer Center (http://derlab.med.utoronto.
ca/CpGIslands.htm) and mapped on the human genome using
Blat (http://genome.ucsc.edu). Approximately 2 kb of genomic
regions 59 and 39 of the CpG islands clones were considered and
one or more Gene ID were assigned to each clone, if they laid in
these regions. GO enrichment analysis was performed at http://
bioinfo.vanderbilt.edu/webgestalt.
RNA profiling
Keratinocytes from three independent healthy donors were
transfected to inactivate C/EBPd. 2 mg of each sample were
pooled, for further processing. For each sample, 500 ng of total
RNA were synthesized to biotinylated cRNA using the Illumina
RNA Amplification Kit (Ambion, USA). Synthesis was carried out
according to the Manufacturers’ instructions. From each sample,
three technical replicates were produced and 750 ng cRNA were
hybridized for 18 hrs to HumanHT12 v. 3.0 Expression
BeadChips (Illumina Inc., USA) according to the protocol
provided by the manufacturer. Hybridized chips were washed
and stained with streptavidin-conjugated Cy3 (GE Healthcare,
USA). BeadChips were dried and scanned with an Illumina
BeadArray Reader (Illumina, USA). For data analysis, the
intensity files were loaded into the Illumina BeadStudio v.
3.1.3.0 software for quality control and gene expression analysis.
First, the quantile normalization algorithm was applied on the
dataset to correct systematic errors. Background is subtracted. For
differential expression analysis, technical replicates of each sample
were grouped together and genes with a detection p-value below
0.01, corresponding to a false positive rate of 1%, were considered
as detected. Differently expressed genes were selected with Diff
Score cutoff set at 630; genes with a differential expression of
.1.5 between siC/EBPd and siScramble were retrieved.
Western blot and Immunohistochemistry
Western blot analysis was performed using standard procedure
with a Pierce secondary antibody and PDS detection system
(Genespin, I).
C/EBPd Targets
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For IHC, tissue samples were fixed in buffered formalin,
dehydrated, embedded in paraffin wax and sectioned. After
deparaffinizing and rehydrating, each tissue section was immersed
in citrate buffer 0.01M pH 6 or EDTA 0.05M pH 8 or Tris-HCl
0.05M pH 9.9, boiled 3 times for 5 minutes in a pressure cooker and
washed with TBS buffer. Each section was placed on the Dako
cytomation automated immunostainer and incubated with the
specific monoclonal antibody at room temperature for 45 minutes,
washed with TBS pH 7.6 and incubated in a biotinylated goat anti-
mouse anti-rabbit immunoglobulins (Dako REALTM, Dako, Dn) at
room temperature for 30 minutes. After incubation with the
secondary antibody and a new wash with TBS pH 7.6, sections
were incubated with streptavidin conjugated to alkaline phospha-
tase at room temperature for 309. A red chromogen solution was
prepared as indicated by Dako REALTM datasheet. Each section
was counterstained in Mayer’s Hematoxylin solution and cover-
slipped. Skin cancer tissue array included 48 cases of normal, benign
and cancerous tissue of the skin and subcutaneous tissues in
duplicates. All the tissues were from surgical resection. They were
fixed in 10% neutral buffered formalin for 24 hours and processed
using identical SOPs. Sections were picked onto Superfrost Plus or
Apes coated Superfrost slides. (Skin Tumor Tissue Array, BioChain,
cat. Z7020093). Anti-C/EBPd antibody (Active Motif, USA) was
used in this analysis, together with the 4A4 anti-p63 as a control.
Results
Identification of C/EBPd loci in human keratinocytes
C/EBPd emerged in expression profilings of human HaCaT and
primary keratinocytes in which p63 was functionally inactivated by
RNAi [21,32]. To identify C/EBPd targets in vivo, we performed
ChIP on chip analysis with a specific antibody on chromatin derived
from keratinocytes of three healthy individuals undergoing plastic
surgery. The enrichment over the Flag control was first tested on
three promoters previously identified as bona fide C/EBPd targets
[21]: Figure 1A shows that TGFbII-R, ESR and Zeb1 promoters,
unlike satellite DNA, are specifically enriched in the C/EBPd IP
with respect to control IP,. We hybridized DNA immunoprecipi-
tated with C/EBPd and Flag control antibodies to the 21K CpG
islands array, together with DNAs from Input controls. With a ratio
of 1.5 enrichment over Inputs, 136 C/EBPd loci were identified.
The sequences of these CpG islands spots were retrieved and
mapped on the human genome (Table S3). For validation of the
ChIP on chip, we selected 13 loci near gene promoters and located
potential C/EBP binding sites by rVista and ConSite [33,34] with
JASPAR. Amplicons were designed in the area and ChIPs from
independent human primary keratinocytes performed. A schematic
representation of the selected promoters, with the position of the
predicted C/EBP sites and the results of the ChIP experiments are
shown in Fig. 2. Ten loci were enriched, one –Gata3- was modestly
enriched, and LTBP and BCOR did not show credible binding, at
least in the region we analyzed. It should be noted that this analysis
is complex, as the bound site(s) could be within 0.5 Kb on either side
of the CpG island clone identified.
Functional mining of the associated genes was performed by
GO analysis and a few terms emerged with a good degree of
robustness: cell cycle, transcription and DNA-damage checkpoint in the
Biological Process category; transcription factor and DNA-binding in
Molecular Function, and nucleus in the Cellular Component
category (Fig. 1B). Comparison with ChIP on chip experiments
performed in mammary cells upon overexpression of C/EBPd
[29] yielded no overlap. The difference in the arrays -12K vs 21K
arrays used in our study- the relative paucity of the targets
identified (100 vs 136) and the difference of the cellular context –
the MCF12A mammary cell line transfected with C/EBPd vs
normal keratinocytes- might account for this finding. Nevertheless,
many GO enriched categories were similar: cell adhesion, cell cycle,
transcription, DNA-damage [29].
Identification of C/EBPd-regulated genes in human
primary keratinocytes
We also sought to identify genes whose expression varies
inactivating C/EBPd in human primary keratinocytes. We RNAi-
inactivated C/EBPd with one of the siRNAs previously tested [21]:
the process was efficient, as checked in RT-PCR and Western blot
analysis (Fig. 3A). Keratinocytes derived from three healthy
individuals undergoing plastic surgery, independent from those
used in ChIP on chips, were transfected with control and C/EBPd
siRNAs, followed by gene expression profiling with the Illumina
platform, in triplicate. For subsequent analysis, we considered a
threshold of 1.5-fold over scramble siRNA samples. Heat maps of
these experiments are shown in Fig. 3B: 420 up-regulated and 163
down-regulated genes were identified (Table S4).
We validated by qRT-PCR 22 genes that decrease upon C/
EBPd removal and 9 that increase: Fig. 3C shows that all genes were
regulated in the expected way. Variation were quantitatively greater
in qRT-PCR compared to the array data, an indication that the
threshold considered is relatively stringent and the cohort of truly
regulated genes is larger. To ascertain whether the genes are direct
targets of ChIPs, we performed ChIPs with chromatin from adult
and neonatal primary keratinocytes on five promoters –Sox2,
TEGT, MafB, TopoIIa and Jag1- with antibodies against C/EBPd;
p63 was used as a positive control, since these genes are also p63
targets. Fig. 3D (Left Panels) shows that most targets are positive,
with the exception of Jag1 in neonatal keratinocytes. In the Right
Panels qPCR analysis was performed on additional targets in adult
keratinocytes and two targets -TIG1 and Hes1- were not validated
in the core promoter region considered. Overall the validation data
support the results of the profiling analysis.
We performed functional mining of the C/EBPd regulated genes
by GO analysis (Figure S1). Among the genes whose expression
increased after C/EBPd removal, hence repressed, the epidermis
development, transcription and cell migration classes emerged with p values
lower than E-05. Among the genes decreased by C/EBPd removal,
therefore normally activated, cell cycle and mitosis were at the top of
the Biological Process list, with lipid biosynthesis, development (ectoderm,
muscle, immune system) having p values lower than E-07. In the Cellular
Component category, we found chromosomal part and spindle, and in
the Molecular Function few terms were enriched. In conclusion, this
analysis is in good accordance with the terms retrieved from the
ChIP on chip experiments, since terms like cell cycle and transcription
predominate. Note, however, that only one gene –MafB- was found
in both lists, possibly due to the use of different genomic platforms.
Comparison between the C/EBPd and p63 targets in
keratinocytes
We have recently shown that some of the targets of p63 are also
influenced by inactivation or overexpression of C/EBPd [21]. We
were therefore interested in verifying the overlap between the p63
targets and the C/EBPd targets identified here. For this analysis,
shown in Figure 4, we considered collectively the targets identified
in various p63 profiling experiments performed with siRNA [32,36–
39]. The coregulated genes are grouped according to the p63 and
C/EBPd effects on them: the larger cohort is represented by genes
that are repressed by p63 and activated by C/EBPd, with only three
genes behaving in the opposite way. Interestingly, several genes are
either repressed or activated by both TFs. These data are in
C/EBPd Targets
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agreement with a different role of the two TFs in keratinocyte
differentiation and with the overlapping expression patterns of p63
and C/EBPd in human interfollicular epidermis [21].
C/EBPd and keratinocyte differentiation
We analyzed the specific role of C/EBPd in keratinocyte
differentiation by transfecting primary keratinocytes with C/EBPd
and scramble siRNAs and inducing differentiation in vitro; we
compared the mRNA levels of differentiation markers in silenced
and control cells. As shown in Fig. 5, qRT-PCR analysis reveals a
substantial increase of the mRNA levels of filaggrin and KRT10
upon differentiation of control cells, but not in cells inactivated for
C/EBPd. On the other hand, the levels of KRT14 modestly
decrease after differentiation in control cells, but not in siRNA-
treated cells, suggesting that C/EBPd indeed affects the expression
of genes that mark keratinocytes differentiation.
Figure 1. Identification of C/EBPd targets by ChIP on chip. A. Generation of the ChIP amplicons for ChIP on chip experiments. ChIP of human
primary keratinocytes with C/EBPd and control antibodies. The known targets tested are indicated. The normalization of the immunoprecipitated
material was performed by evaluating a negative genomic region (Centromeric Satellite 11). B. Gene Ontology analysis of C/EBPd targets genes from
the ChIP on chip screening.
doi:10.1371/journal.pone.0013789.g001
C/EBPd Targets
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Role of C/EBPd targets Sox2 and MafB, in keratinocyte
differentiation
We further analyzed two C/EBPd target genes -Sox2 and
MafB- to verify their function in keratinocytes differentiation. Sox2
is one of the genes that leads to reprogramming of differentiated
cells to pluripotent ES-like cells [40]. MafB is a TF with a role in
the development and differentiation of several tissues [41]. The
former is repressed by C/EBPd, the latter activated. We
transiently transfected primary keratinocytes with Sox2 and MafB
expression vectors, evaluating by qRT-PCR the levels of
endogenous markers of keratinocytes differentiation (Fig. 6):
Sox2 caused a decrease of filaggrin and KRT10, whereas MafB
overexpression resulted in higher levels of filaggrin and KRT10.
The changes in the basal layer marker KRT14 were modest.
These data suggest the levels of two TFs regulated by C/EBPd
impact on the expression of markers of differentiation.
Figure 2. Validation of C/EBPd targets in primary keratinocytes. A. Analysis of the loci targeted derived from the ChIP on chip experiments
by qPCR analysis of ChIPs with anti-C/EBPd and control antibodies from human primary keratinocytes. B. The position of the ampolicons (black bars)
and of the putative C/EBP consensus site (circle) are indicated for targets analyzed in A.
doi:10.1371/journal.pone.0013789.g002
C/EBPd Targets
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Figure 3. Identification of C/EBPd-regulated genes in human keratinocytes. A. Left Panels, RT-PCR analysis of human primary keratinocytes
after C/EBPd RNAi inactivation at 48 hours post-transfection. cDNA normalization was performed with GAPDH. Right Panels, Western Blot analysis of
the same C/EBPd-inactivated human primary keratinocytes with the C/EBPd antibody. Vinculin was used as a loading control. B. Heat map showing
the mRNA expression levels of several classes of genes after C/EBPd inactivation. C. qRT-PCR analysis of C/EBPd regulated genes that emerged from
the expression profiling. D. ChIP analysis of promoter regions of C/EBPd-regulated genes with chromatin from human primary keratinocytes, with a-
C/EBPd and control antibodies. In the Left Panel, adult and neonatal keratinocytes were analyzed in semi-quantitative PCR. In the Right Panel, the
targets were validated by qPCR in adult keratinocytes.
doi:10.1371/journal.pone.0013789.g003
C/EBPd Targets
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Figure 4. C/EBPd and p63 regulated genes. Genes coregulated by p63 and C/EBPd, either activated or repressed (Table S2). The data on p63
were derived from References 32, 36–39.
doi:10.1371/journal.pone.0013789.g004
Figure 5. C/EBPd is important for keratinocyte differentiation. Analysis of differentiation markers by qRT-PCR of C/EBPd-inactivated cells
induced to differentiate. Primary keratinocytes were transfected with scamble and C/EBPd siRNAs. After 24 h, half of the cells were induced to
differentiate by addition of calcium. Samples were harvested after 3 days, RNAs prepared and qPCR performed on the indicated genes. Values are
normalized to GAPDH, used as an internal control.
doi:10.1371/journal.pone.0013789.g005
C/EBPd Targets
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C/EBPd is differentially expressed in human skin tumors
The expression of C/EBPa and b is altered in several tumors,
including those of epithelial origin [23–27]. Nothing is known
about the expression of C/EBPd in various types of skin tumors.
We decided to analyze its expression in a panel of different skin
tumors by immunohistochemistry (IHC); the results are shown in
Figure S2: 0 is no expression, and 3 is maximum positivity. Most
Squamous Cell Carcinomas -SCC- show overexpression of C/
EBPd (14 out of 20); as expected, p63 levels were also generally
high [42]. On the other hand, Basal Cell Carcinomas were
negative for C/EBPd expression, whereas p63 expression was very
high. Figure 7 shows the IHC staining of representative cases of
SCC and BCC, and comparison with normal skin. In conclusion,
these data indicate that, unlike p63, C/EBPd is differentially
expressed in human BCC and SCC tumors and, like the related
C/EBPb, overexpressed in SCC.
Discussion
The modulation of gene expression in growth and differentiation
is controlled by transcription factors. In tissues in which these
processes are continuously active to provide the required mass of
specialized cells, many TFs contribute, with distinct yet partially
overlapping programs. Hierarchical models have been suggested
that specific TFs account for differentiation programs in a multistep
way. This matter is complicated by the fact that TFs come in
families, with members often being apparently redundant. In
multilayered epithelia, it is clear that p63 plays a role that cannot be
vicariate by other members of the family, p53 or p73. The recent
identification of p63 targets provided links with other TFs that play
an important role in skin biology, notably C/EBPs [21,35].
C/EBPd and keratinocyte differentiation
C/EBPd belongs to a family of TFs important for several
differentiation pathways, including adipocytes, liver and haema-
topoietic lineages [2]. C/EBPd and C/EBPb are structurally the
two closest members and genetic experiments have linked them to
the early phases of adipocyte differentiation, with redundant roles
[6]. Neither C/EBPb nor C/EBPd KO mice show a skin
phenotype, possibly because of redundancy. Double C/EBPa/
C/EBPb KO have profound skin defects, with lack of complete
differentiation and increased proliferation of basal layer cells,
associated to increased p63 expression [18]. Among the estab-
lished targets of C/EBPs are desmocollins, which are required for
skin desmosome formation. Desmocollin 3, which is expressed in
basal cells, is transactivated by C/EBPd and C/EBPb, the
suprabasal Desmocollin 1 by C/EBPd and C/EBPa [43]. In
humans, little variation of expression of C/EBPd was detected in
the different phases of maturation of skin annexes, the hair follicle
and the sebaceous gland, unlike other members of the family [44].
However, we observed that C/EBPd staining is not uniform in
human interfollicular skin. Co-expression with the growth
Figure 6. Role of C/EBPd target genes in keratinocyte differentiation. A. Analysis of differentiation markers by qRT-PCR of primary
keratinocytes induced to differentiate after transient transfection of MafB expression plasmid and empty vector as control. After 24 h, half of the cells
were induced to differentiate by addition of calcium, as in Fig. 5. B. Same as A, except that Sox2 was overexpressed.
doi:10.1371/journal.pone.0013789.g006
C/EBPd Targets
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promoting p63 is seen only in selected basal cells, it is balanced in
the spinous layer, and in the upper granular layer, C/EBPd
predominates [21]. Among the many genes targeted by C/EBPd
and p63, the vast majority is controlled in an opposite way by the
two TFs, which is consistent with their overlapping expression
patterns in the skin.
Many genes activated by C/EBPd in our experiments are
involved in functions of the granular layer and in the formation of
the skin barrier (Fig. 8). SPRRs, RARRES3 and COX-2 are
expressed in the granular layer and involved in differentiation [44–
49]. KRT4 is a developmentally regulated Keratin, required for
proper differentiation of internal multi-layered epithelia (50).
Spink proteins are serine protease inhibitors involved in skin
barrier formation: mutations in the Spink5 –LEKTI- gene in
humans cause the Netherton syndrome, an ichthyosiform
dermatosis (51); Spink5 KO mice have severe alteration in the
Stratum Corneum (SC) [52–54]. Spink targets, such as KLK4, a
serine protease implicated in the desquamation, are repressed by
C/EBPd [55]. BMP6 is a signaling molecule that inhibits stem cell
proliferation and triggers cell cycle exit from transit amplifying
cells [56]. KRT10, Loricrin and Late Cornified Envelope group,
LCE1F, LCE3A and LCE3C are markers of the suprabasal layers
[57]. The experiments of Fig. 5 confirm that KRT10 expression is
affected by C/EBPd removal. In summary, C/EBPd joins the list
Figure 7. Overexpression of C/EBPd in human non-melanoma skin tumors. Immunohistochemistry analysis of p63 and C/EBPd in normal
skin (Upper Panel), BCC (Middle Panel) and SCC (Lower Panel).
doi:10.1371/journal.pone.0013789.g007
C/EBPd Targets
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of other TFs involved in barrier formation, such as IRF6 [58,59],
KLF4 [60], Gata3 [61,62] and HBP1 [63]. Each is likely to
promote the expression of subsets of differentiation genes.
Importantly, KLF4, Gata3 and HBP1 are directly controlled by
p63 [62–64].
C/EBPd and control of proliferation
To induce terminal differentiation, proliferation must be
stopped: C/EBPs are largely thought to be growth suppressors.
Experiments performed in cultured cells in vitro as well as in mice in
vivo have generally supported this idea. Mechanisms related to
control of cell cycle progression, rather than induction of apoptosis
or senescence, have been suggested. The mechanistic details are
apparently multiple, and range from a direct role on CDKs, to
activation of CDKI genes, to repression of growth stimulatory
genes [65]. Comparatively less is known about C/EBPd, but the
available data fully support this idea: it is induced upon several
environmental changes that lead to growth arrest in mammary
and lung epithelial cells [66]. Overexpression leads to growth
arrest in mammary and prostate epithelial cell lines [67–70]. It was
therefore somewhat expected that cell cycle terms would emerge
from our analysis on C/EBPd targets. However, the strong
emphasis on G2/M genes is novel and unexpected, genes involved
in kinetokore function during mitosis, such as BUB1, Aurora
Kinase B and Borealin-CDCA8, as part of the CPC complex,
KNTC1-ROD, genes recruited by AurKB, CENPF, consensins/
NCAPD2 [71–73], as well as Cyclin B2, Cyclin A, CDKN3-KAP,
CDC20. These findings could explain the chromosomal instability
in mammary cells upon removal of C/EBPd [74].
The Notch, Wnt and TGFb pathways are well represented -
Notch1, Hes1, JAG1, SMAD3, BMP6, FRAT1, LTBP1, Sall4- as
expected for a TF with a global outlook. Growth suppressor genes
are activated by C/EBPd in primary keratinocytes: EDG-8 [75],
STAT2, a TF expressed in the granular layer of the skin [76],
E2F2 and IRF1. Specifically, E2F2 functions as a tumor
suppressor in the skin, since inactivation cooperates with
transgenic expression of Myc to enhance tumor development.
Hemizygous E2f2+/2 mice showed increased tumor incidence.
E2F2 inactivation apparently modifies gene expression patterns of
some Myc targets [77]. IRF-1, also a target of p63, together with
another member of the family, IRF-3 [35], is expressed
throughout human skin [78] and it is generally considered a
growth suppressor [79]. Yet, IRF1 is overexpressed in profiling
experiments of Squamous Cell Carcinomas, amid other IFN-
activated signature genes [80].
Among the genes repressed by C/EBPd, three genes, apparently
not expressed in the skin, stand out because of their role in stem
cells: Sox2, Sall4 and BCOR. Sox2 and Sall4 are TFs that
reprogram differentiated cells, including keratinocytes, to Embry-
onic Stem cells-like iPS, [81,82]. BCOR is a marker of
mesenchimal stem cells [83]. We specifically tested Sox2 and
indeed overexpression has negative consequences on the expres-
sion of markers of terminal differentiation, Filaggrin and KRT10.
An opposite result was obtained with MafB. This latter TF was
more efficient in repressing the levels of the basal marker KRT14
before and after differentiation. MafB is a member of the large
leucine zipper AP1 family, and specifically of the MAF subfamily
[41]. MafB, as well as c-Maf, are highly expressed in basal
keratinocytes and in the hair follicle at the late embryo stage,
dropping after birth [84]. Genetic data generated by analysis of
KO mice of other MAFs –Nrf2, MafG, MafK and the negative
regulator Keap1- indicate that several members play a role in
multilayered epithelia, notably of the esophagus [85].
C/EBPs expression is altered in many tumors, notably of
epithelial origin [23–27]. In general, lack of expression has been
reported which, in the case of C/EBPd in cervical carcinomas, is
caused by epigenetic silencing due to both DNA methylation of
CpG islands and PcG-mediated deposition of negative histone
marks [86]. Our analysis of non-melanoma skin cancers show that
BCC are negative, but the majority of SCCs have relatively high
levels of C/EBPd, especially in areas of ongoing differentiation.
Indeed, oncogenes, such as FRAT1, MALT1 and the TFs
HOXB4, Sall4 and PTTG1 [87–89] are among the targets.
KLF4 is another example of a TF with strong growth suppressive
and pro-differentiation activities, that is nevertheless associated to
tumor promoting functions in specific contexts. Our findings
suggest that C/EBPd could play different roles, depending upon
the tissue context. More generally, it could serve a dual role in skin
homeostasis, both in very early and late stages. In the former, it
could limit, through its suppressive properties, the growth potential
of early progenitors. In the later stages, it may coordinate cell-cycle
exit and induce differentiation markers.
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